MegAb Membrane Protein Antibody Discovery Platform (Proprietary)
Currently, there are three major pain points in the discovery process of membrane protein antibodies (especially GPCRs):
1. Lack of highly immunogenic antigens
2. Lack of antigens that enhance antibody specificity
3. Lack of efficient screening methods for membrane protein antibodies
To address these pain points, we developed the MegAb membrane protein antibody discovery platform based on the MegaR technology platform:
UltraVLP
We developed UltraVLP (virus-like particles) to address the issue of low immunogenicity of antigens. What makes these UltraVLP unique is that they incorporate immune-enhancing components, significantly boosting the immune response to membrane proteins.
Aqua VLP
We developed AquaVLP (virus-like particles) to improve the specificity of antibodies. The uniqueness of these AquaVLP lies in the fact that we have reconstructed purified membrane proteins within them, achieving over 90% representation of the target protein compared to traditional VLPs. This innovative approach significantly enhances the specific immune response to the target protein.
Purified GPCRs for hybridoma / B cell screening
Unlike other companies that can only use cell membrane fragments or cells for antibody screening during the development of antibodies against membrane proteins (especially GPCRs), Alphelix can easily and quickly use purified membrane proteins for antibody screening. Ultimately, we have greatly improved the efficiency of therapeutic antibody development for membrane proteins through traditional hybridoma technology or microdroplet/microfluidic high-throughput sorting technology.
